ALEFACEPT PROMOTES COSTIMULATION BLOCKADE BASED ALLOGRAFT SURVIVAL IN PRIMATES

Memory T-cells promote allograft rejection particularly in costimulation blockade (CoB)-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (LFA3-Ig) selectively eliminates memory T-cells and when combined with a CoB-based regimen utilizing CTLA4-Ig, prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Weaver, T.A., Charafeddine, A.H., Agarwal, A., Turner, A.P., Russell, M., Leopardi, F.V., Kampen, R.L., Stempora, L., Song, M., Larsen, C.P., Kirk, A.D.
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2772128/
https://www.ncbi.nlm.nih.gov/pubmed/19584865
http://dx.doi.org/10.1038/nm.1993
Descripción
Sumario:Memory T-cells promote allograft rejection particularly in costimulation blockade (CoB)-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (LFA3-Ig) selectively eliminates memory T-cells and when combined with a CoB-based regimen utilizing CTLA4-Ig, prevents renal allograft rejection and alloantibody formation in primates. These results support the development of an immediately translatable regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids, or pan-T-cell depletion.

Ejemplares similares